Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Olalekan O. Oluwole, Rongzhe Liu, Ibrahim Diakite, Chaoling Feng, Anik Patel, Iman Nourhussein, Julia Thornton Snider & Frederick L. Locke. (2022) Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US. Journal of Medical Economics 25:1, pages 541-551.
Read now
Read now
Xiao Jun Wang, Yi-Ho Wang, Shing Chau Tony Li, Christina Gkitzia, Soon Thye Lim, Liang Piu Koh, Francesca Lorraine Wei Inng Lim & William Ying Khee Hwang. (2021) Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore’s private insurance payer’s perspective. Journal of Medical Economics 24:1, pages 637-653.
Read now
Read now
Kishan K. Patel, Iris Isufi, Shalin Kothari, Francine Foss & Scott Huntington. (2020) Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. Leukemia & Lymphoma 61:14, pages 3387-3394.
Read now
Read now
Hongbo Yang, Yanni Hao, Xinglei Chai, Cynthia Z. Qi & Eric Q. Wu. (2020) Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital’s perspective. Journal of Medical Economics 23:9, pages 1016-1024.
Read now
Read now
R. Andrew Harkins, Sharvil P. Patel & Christopher R. Flowers. (2019) Cost burden of diffuse large B-cell lymphoma. Expert Review of Pharmacoeconomics & Outcomes Research 19:6, pages 645-661.
Read now
Read now
Articles from other publishers (12)
John M. Burke, Anthony Masaquel, Rongrong Wang, Farah Hossain, Jia Li, Summera Qiheng Zhou, Carmen D. Ng & Matthew Matasar. (2023) Cost of Disease Progression in Diffuse Large B-Cell Lymphoma After Frontline Treatment With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. Clinical Lymphoma Myeloma and Leukemia 23:11, pages e393-e404.
Crossref
Crossref
Swetha Kambhampati, Evgenii Shumilov, Monica Saumoy, Alex F. Herrera, Hervé Tilly, Georg Lenz & Nikhil R. Thiruvengadam. (2023)
Cost‐effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola‐
R‐CHP
) in previously untreated diffuse large B‐cell lymphoma in Germany
. British Journal of Haematology 202:4, pages 771-775.
Crossref
Crossref
Roxanna Seyedin, Julia T Snider, Krithika Rajagopalan, Sally W Wade & Usama Gergis. (2023) Chimeric antigen receptor T-cell treatment patterns in relapsed or refractory large B-cell lymphoma. Future Oncology 19:22, pages 1535-1547.
Crossref
Crossref
Peter Borchmann, Jan-Michel Heger, Jörg Mahlich, Michael S. Papadimitrious, Sybille Riou & Barbara Werner. (2022) Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Health Claims Data Analysis. Oncology and Therapy 11:1, pages 65-81.
Crossref
Crossref
Swetha Kambhampati, Monica Saumoy, Yecheskel Schneider, Stacy Pak, Lihua Elizabeth Budde, Matthew G. Mei, Tanya Siddiqi, Leslie L. Popplewell, Yi-Ping Wen, Jasmine Zain, Stephen J. Forman, Larry W. Kwak, Steven T. Rosen, Alexey V. Danilov, Alex F. Herrera & Nikhil R. Thiruvengadam. (2022) Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma. Blood 140:25, pages 2697-2708.
Crossref
Crossref
Jee H. Choe, Hisham Abdel-Azim, William V. Padula & Mohamed Abou-el-Enein. (2022) Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. JAMA Network Open 5:12, pages e2245956.
Crossref
Crossref
Swetha Kambhampati, Monica Saumoy, Yecheskel Schneider, Steve Serrao, Pejman Solaimani, Lihua Elizabeth Budde, Matthew G. Mei, Leslie L. Popplewell, Tanya Siddiqi, Jasmine Zain, Stephen J. Forman, Larry W. Kwak, Steven T. Rosen, Alexey V. Danilov, Alex F. Herrera & Nikhil R. Thiruvengadam. (2022) Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma. Blood 140:19, pages 2024-2036.
Crossref
Crossref
Saaya Tsutsué, Shinichi Makita, Jingbo Yi & Bruce Crawford. (2022) Cost drivers associated with diffuse large B-cell lymphoma (DLBCL) in Japan: A structural equation model (SEM) analysis. PLOS ONE 17:5, pages e0269169.
Crossref
Crossref
Julia Thornton Snider, Donna McMorrow, Xue Song, David Diakun, Sally W. Wade & Paul Cheng. (2022) Burden of Illness and Treatment Patterns in Second-line Large B-cell Lymphoma. Clinical Therapeutics 44:4, pages 521-538.
Crossref
Crossref
Cynthia Z. Qi, Vamsi Bollu, Hongbo Yang, Anand Dalal, Su Zhang & Jie Zhang. (2021) Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States. Clinical Therapeutics 43:8, pages 1300-1319.e8.
Crossref
Crossref
Keith A Betts, Per-Olof Thuresson, Federico Felizzi, Ella X Du, Ibou Dieye, Jia Li, Mathias Schulz & Anthony S Masaquel. (2020) US cost–effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma. Journal of Comparative Effectiveness Research 9:14, pages 1003-1015.
Crossref
Crossref
John K. Lin, Lori S. Muffly, Michael A. Spinner, James I. Barnes, Douglas K. Owens & Jeremy D. Goldhaber-Fiebert. (2019) Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma. Journal of Clinical Oncology 37:24, pages 2105-2119.
Crossref
Crossref